Phaseline

Targets › FCER2

FCER2 (Low affinity immunoglobulin epsilon Fc receptor): drug programs, companies and trials

2 programs from 2 companies in 5 trials: 3 Phase 3, 2 Phase 2; Neurology; next expected readout Dec 2026.

Low-affinity receptor for immunoglobulin E (IgE) and CR2/CD21. Has essential roles in the regulation of IgE production and in the differentiation of B cells. (UniProt, P06734)

Open in Phaseline: the race on FCER2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Dianthus TherapeuticsClaseprubart
complement C5 inhibitor
FCER2, COMPPhase 3Myasthenia Gravis, Generalized; Chronic Inflammatory Demyelinating Polyneuropathy; Multifocal Motor NeuropathyDec 2026
AstraZenecagefurulimab
CD23 antagonist monoclonal antibody
FCER2Phase 3Generalized Myasthenia GravisDec 2026

Conditions

Myasthenia Gravis, Generalized (2) Chronic Inflammatory Demyelinating Polyneuropathy (1) Multifocal Motor Neuropathy (1) Generalized Myasthenia Gravis (1)

Modalities

antibody (2)

Companies

Dianthus Therapeutics (1) AstraZeneca (1)

Related targets

COMP (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.